G-BA restricts prescribing of the new Alzheimer's drugs lecanemab and donanemab under Annex III AM-RL

The prescribing restriction was made because of the only mild to moderate effectiveness, the strong differences in how well the drugs work from patient to patient, and the side effects of these Alzheimer's drugs, which cannot be ignored. It ensures that these drugs are only used when a positive effect on the course of the disease can be confirmed that justifies continued treatment.

To keep prescribing these drugs, doctors must regularly check whether they are preventing the progression to moderate Alzheimer's disease. For lecanemab, this check must happen at least every 6 months. The maximum treatment duration with donanemab is 18 months.